Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases

by Garth Sundem,CU Anschutz Medical CampusRobert C. Doebele, MD, PhD. Credit: CU Anschutz Medical CampusPooled analysis of three phase 1 and 2 clinical trials published online ahead of print in

Updated on: December 22,2023

Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases

by Garth Sundem,CU Anschutz Medical CampusRobert C. Doebele, MD, PhD. Credit: CU Anschutz Medical CampusPooled analysis of three phase 1 and 2 clinical trials published online ahead of print in

Updated on:December 22,2023

New study seeks hereditary causes of childhood cancer

byKarolinska InstitutetOverview of study design and study cohort. Credit:The Lancet Regional Health—Europe(2024). DOI: 10.1016/j.lanepe.2024.100881Follow-up and treatment of children

Updated on: April 28,2024

New study seeks hereditary causes of childhood cancer

byKarolinska InstitutetOverview of study design and study cohort. Credit:The Lancet Regional Health—Europe(2024). DOI: 10.1016/j.lanepe.2024.100881Follow-up and treatment of children

Updated on:April 28,2024

Causes and Risk Factors of Non-Small Cell Lung Cancer

Causes and Risk Factors of Non-Small Cell Lung CancerByLynne Eldridge, MDUpdated on July 16, 2021Medically reviewed byDoru Paul, MDWhile the exact causes ofnon-small cell

Updated on: January 28,2024

Causes and Risk Factors of Non-Small Cell Lung Cancer

Causes and Risk Factors of Non-Small Cell Lung CancerByLynne Eldridge, MDUpdated on July 16, 2021Medically reviewed byDoru Paul, MDWhile the exact causes ofnon-small cell

Updated on:January 28,2024

Shutting down backup genes leads to cancer remission in mice

by Jim Lynch,University of MichiganAbhinav Achreja, PhD, Research Fellow at the University of Michigan Biomedical Engineering and Deepak Nagrath, Ph.D. Associate Professor of Biomedical Engineer

Updated on: December 22,2023

Shutting down backup genes leads to cancer remission in mice

by Jim Lynch,University of MichiganAbhinav Achreja, PhD, Research Fellow at the University of Michigan Biomedical Engineering and Deepak Nagrath, Ph.D. Associate Professor of Biomedical Engineer

Updated on:December 22,2023

Overlooked strategy shows promise for treating KRAS-mutated colon cancer

Updated on: June 14,2025

Overlooked strategy shows promise for treating KRAS-mutated colon cancer

Updated on:June 14,2025

Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m

Updated on: December 22,2023

Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m

Updated on:December 22,2023

Treatment of aggressive breast cancer improved by immunotherapy-chemotherapy combination

byUniversity of Pittsburgh Schools of the Health SciencesLeisha Emens, M.D., Ph.D., co-leader of the UPMC Hillman Cancer Immunology and Immunotherapy Program. Credit: UPMCPatients with an aggres

Updated on: December 18,2023

Treatment of aggressive breast cancer improved by immunotherapy-chemotherapy combination

byUniversity of Pittsburgh Schools of the Health SciencesLeisha Emens, M.D., Ph.D., co-leader of the UPMC Hillman Cancer Immunology and Immunotherapy Program. Credit: UPMCPatients with an aggres

Updated on:December 18,2023

Why alarm is easing over a rise in pancreatic cancer among the young

by Robin FosterExperts have been concerned by rising rates of pancreatic cancer in young adults, but new research reveals the jump in cases has not been accompanied by any increase in deaths from the

Updated on: December 02,2024

Why alarm is easing over a rise in pancreatic cancer among the young

by Robin FosterExperts have been concerned by rising rates of pancreatic cancer in young adults, but new research reveals the jump in cases has not been accompanied by any increase in deaths from the

Updated on:December 02,2024

MRD Could Play Role in Predicting Post-ASCT Outcomes in Myeloma

September 9, 2021Darlene Dobkowski, MAFor patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease m

Updated on: October 24,2023

MRD Could Play Role in Predicting Post-ASCT Outcomes in Myeloma

September 9, 2021Darlene Dobkowski, MAFor patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease m

Updated on:October 24,2023

A promising treatment for ovarian cancer

by Erin Matthews,Canadian Light SourceOvary. Credit: Public DomainOver 20,000 women across the U.S. and Canada are diagnosed with ovarian cancer annually. The symptoms of this disease are often

Updated on: March 12,2024

A promising treatment for ovarian cancer

by Erin Matthews,Canadian Light SourceOvary. Credit: Public DomainOver 20,000 women across the U.S. and Canada are diagnosed with ovarian cancer annually. The symptoms of this disease are often

Updated on:March 12,2024

GZ17-6.02 with bexarotene kills mycosis fungoides cells: Study

by Impact Journals LLCCombined macroautophagy and CD95 death receptor signaling facilitate additional tumor cell killing by GZ17-6.02. Credit: 2024 Booth et al.A new research paper titled "GZ17-6

Updated on: May 26,2024

GZ17-6.02 with bexarotene kills mycosis fungoides cells: Study

by Impact Journals LLCCombined macroautophagy and CD95 death receptor signaling facilitate additional tumor cell killing by GZ17-6.02. Credit: 2024 Booth et al.A new research paper titled "GZ17-6

Updated on:May 26,2024

COVID-19 antiviral treatment should be taken for longer, says study

by University College LondonViral and spike antibody dynamics in molnupiravir (purple) and Usual Care (gray) arms. a) Median viral load ±95%CI with time, below limit of quantification (BLOQ) meas

Updated on: May 11,2024

COVID-19 antiviral treatment should be taken for longer, says study

by University College LondonViral and spike antibody dynamics in molnupiravir (purple) and Usual Care (gray) arms. a) Median viral load ±95%CI with time, below limit of quantification (BLOQ) meas

Updated on:May 11,2024